26 October, 2020 | ChargePoint Technology
Eleven of the current 15 top selling drugs are biopharmaceuticals, meaning the biopharmaceutical market is facing increased demand for innovation. Operational efficiencies, quality control and cost reductions are also key considerations for manufacturers alongside the challenge of eliminating the risk of product contamination.
In an article with Contract Pharma, our global head of sterile solutions, Christian Dunne, discussed how sterile manufacturing is becoming more popular and that the implementation of split butterfly valve (SBV) technology could solve these challenges and ensure product sterility in manufacturing.
Read the article here: https://bit.ly/33RB9qo